WIB for Business – Partner in the Development of Biomedical Innovation and Technology Commercialisation

The Virtual Research Institute (WIB) offers biotechnology and pharmaceutical companies, CROs, investors and business support institutions access to innovative R&D projects, biomedical technologies and opportunities for collaboration in commercialisation, technology transfer and acceleration.

Virtual Research Institute – an ecosystem for biomedical innovation

The Virtual Research Institute (WIB) is a programme that combines long-term funding for biomedical research with tangible support for the commercialisation of innovative technologies. Powered by leading Polish research teams and operated by Łukasiewicz – PORT, WIB is a trusted partner for organisations across biotech, pharma, medtech and investment sectors.

WIB focuses on projects with the highest implementation potential – from new drugs and advanced therapies, through diagnostic technologies, to innovative solutions in personalised medicine. It is a space where science meets industry, creating projects ready to enter the domestic and global markets.

Collaboration with biotechnology and pharmaceutical companies

Gain a competitive edge with access to high-quality, validated R&D projects developed within a stable, multi-year funding framework. WIB ensures continuity, scientific excellence and strong technological validation at every stage.

Access to innovative R&D projects ready for commercialization

Key benefits for business:

direct access to innovative biomedical technologies with strong implementation potential,
licensing opportunities and flexible co-development mode
projects with validated, high-quality of preclinical data,
support in assessing Technology Readiness Levels (TRL) and designing translation pathways,
integration into a powerful network of experts, labs and industry partners.

WIB is an attractive source of new technologies for companies seeking mature, innovative biomedical projects to strengthen their research or commercial portfolios.

Technology licensing and co-development partnerships

WIB for CROs and clinical research centres

WIB projects are designed to move forward – fast. Their maturity naturally leads to clinical trial prep readiness, opening up immediate collaboration opportunities. We collaborate with:

CROs,
hospitals and clinical centers,
operators of early-phase research infrastructure.

What WIB offers clinical partners:

access to a pipeline of technologies ready for Phase I/II clinical trials,
research teams prepared for regulatory and clinical collaboration,
transparent quality, process and preclinical documentation,
alignment with EMA/FDA requirements from early stages.

This provides CROs with access to a stable pipeline of innovative projects, while clinical centres gain participation in the development of new therapies and diagnostics.

WIB for investors, VC/CVC funds and business support institutions

WIB generates projects with strong investment potential, sustable for:

VC and CVC funds,
sector-specific investors (biotech, medtech, pharma),
Innovation-driven institutions,
deep-tech ecosystem players.

High-value projects, spin-off creation and deep-tech development

The programme provides:

access to projects with reduced technological risk (through expert validation),
full transparency of research and reporting process,
readiness for spin-off creation,
structured support for scaling and commercialisation/market entry.

WIB bridges the gap between science and business, enabling effective technology transfer and the development of innovative life sciences ventures.

Acceleration of medical innovation – national and international cooperation

Łukasiewicz – PORT actively develops partnerships with domestic and international acceleration programmes, incubators and innovation-support funds.

Acceleration programmes in Poland and abroad

In this area WIB offers:

preparation for leading acceleration programmes in Poland and abroad,
access to global business and industry network,
access to public and private funding sources.

As a result, technologies developed within WIB reach commercialisation readiness more quickly.

Development of technological, clinical and business maturity (TRL/CRL/BRL)

Development of competencies across technological, clinical, business and regulatory areas.
Mentoring from top experts in life sciences, VC and industry.
Support in developing market entry strategies and regulatory pathways.

Why collaborate with WIB?

Strong pipeline of market-ready biomedical innovations.
Long-term, stable R&D funding.
Guidance by leading international experts.
The experience of the operator – Łukasiewicz – PORT, a centre for commercialisation and technology transfer.
Seamless collaboration between science, business, investors, and clinical partners.
Clear implementation focus – every WIB project has a commercial goal.

WIB is a place where technologies shaping the future of medicine are created – open to collaboration with business partners at every stage of innovation development.

Key value for business

Biomedical technology pipeline,
High-quality, trusted R&D data,
Access to top-tier expertise and infrastructure,
Transparent, secure processes,
A complete ecosystem for commercialisation success.

Let’s build the future of medicine together

e-mail: wib_komercjalizacja@port.lukasiewicz.gov.pl

tel: + 48 71 73 47 668